Allarity Therapeutics Inc
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib… Read more
Allarity Therapeutics Inc (ALLR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.284x
Based on the latest financial reports, Allarity Therapeutics Inc (ALLR) has a cash flow conversion efficiency ratio of -0.284x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-3.41 Million) by net assets ($12.01 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Allarity Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Allarity Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Allarity Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Allarity Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
FKS Food Sejahtera Tbk PT
JK:AISA
|
0.005x |
|
Pasupati Acrylon Limited
NSE:PASUPTAC
|
0.008x |
|
Anthem Biosciences Ltd
NSE:ANTHEM
|
N/A |
|
Acer Gadget Inc
TW:2432
|
0.198x |
|
Manba Finance Ltd
NSE:MANBA
|
N/A |
|
Taiwan Auto-Design Co.
TWO:6791
|
-0.073x |
|
Selva Gida Sanayi AS
IS:SELVA
|
-0.049x |
|
Viceroy Hotels Limited
NSE:VHLTD
|
0.144x |
Annual Cash Flow Conversion Efficiency for Allarity Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Allarity Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $11.81 Million | $-17.35 Million | -1.469x | -131.71% |
| 2023-12-31 | $-2.75 Million | $-12.74 Million | 4.633x | +152.07% |
| 2022-12-31 | $1.89 Million | $-16.82 Million | -8.898x | -1010.55% |
| 2021-12-31 | $18.78 Million | $-15.05 Million | -0.801x | -196.70% |
| 2020-12-31 | $26.85 Million | $-7.25 Million | -0.270x | +44.18% |
| 2019-12-31 | $20.90 Million | $-10.11 Million | -0.484x | -218.50% |
| 2018-12-31 | $27.90 Million | $-4.24 Million | -0.152x | +95.55% |
| 2017-12-31 | $394.04K | $-1.34 Million | -3.413x | -346.16% |
| 2016-12-31 | $5.20 Million | $-3.98 Million | -0.765x | -85.86% |
| 2015-12-31 | $4.93 Million | $-2.03 Million | -0.412x | -- |